Quick Answer
PTC THERAPEUTICS, INC. reported Operating Income Loss of $866.94 million for the year ending 2025.
- PTC THERAPEUTICS, INC. showed an increase of +386.5% in Operating Income Loss from 2024 to 2025.
- This data is from PTC THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$14.21 million | Q2 2014: -$25.37 million | Q3 2014: -$27.60 million | Q4 2014: -$32.23 million | Q1 2015: -$38.07 million | Q2 2015: -$38.63 million | Q3 2015: -$42.23 million | Q4 2015: -$48.20 million | Q1 2016: -$38.44 million | Q2 2016: -$36.56 million | Q3 2016: -$32.06 million | Q4 2016: -$24.99 million | Q1 2017: -$26.36 million | Q2 2017: -$12.50 million | Q3 2017: -$30.89 million | Q4 2017: $5.45 million | Q1 2018: -$16.74 million | Q2 2018: -$5.57 million | Q3 2018: -$48.23 million | Q4 2018: -$45.14 million | Q1 2019: -$69.14 million | Q2 2019: -$38.76 million | Q3 2019: -$60.48 million | Q4 2019: -$72.78 million | Q1 2020: -$92.99 million | Q2 2020: -$187.27 million | Q3 2020: -$55.13 million | Q4 2020: -$96.37 million | Q1 2021: -$98.15 million | Q2 2021: -$98.49 million | Q3 2021: -$93.08 million | Q1 2022: -$86.52 million | Q2 2022: -$92.36 million | Q3 2022: -$68.19 million | Q1 2023: -$117.62 million | Q2 2023: -$209.54 million | Q3 2023: -$118.16 million | Q1 2024: -$45.45 million | Q2 2024: -$40.22 million | Q3 2024: -$54.51 million | Q1 2025: $970.23 million | Q2 2025: -$34.96 million | Q3 2025: $3.02 million.
- Over the full 15 years of available data (2011 to 2025), PTC THERAPEUTICS, INC.'s Operating Income Loss has grown by 2,734.8%.
- Historical annual values: Fiscal year 2025: $866.94 million | Fiscal year 2024: -$302.57 million | Fiscal year 2023: -$439.50 million | Fiscal year 2022: -$447.41 million | Fiscal year 2021: -$374.44 million | Fiscal year 2020: -$431.77 million | Fiscal year 2019: -$241.16 million | Fiscal year 2018: -$115.69 million | Fiscal year 2017: -$64.29 million | Fiscal year 2016: -$132.06 million | Fiscal year 2015: -$167.13 million | Fiscal year 2014: -$99.41 million | Fiscal year 2013: -$45.40 million | Fiscal year 2012: -$26.81 million | Fiscal year 2011: $30.58 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: